OXiGENE is a pharmaceutical company that develops novel small-molecule therapeutics to treat cancer and eye diseases. The company s major focus is the clinical advancement of drug candidates that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. The company s flagship compound, Combretastatin CA4 Prodrug, is a cancer treatment based on vascular targeting agents. OXiGENE also evaluates the use of its vascular targeting agents in an ophthalmology setting. Similar to CA4P's ability to target and disrupt abnormal tumor blood vessels, it has been shown in preclinical studies to suppress development and induce regression of the recently formed and abnormal blood vessels that occur in certain eye diseases. OXiGENE maintains its headquarters, laboratory and research and development facilities in Waltham, Mass.
Partial Data by Infogroup (c) 2024. All rights reserved.
